about
Lithium in drinking water and suicide mortality.Reduced serotonin-1A receptor binding in social anxiety disorder.Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers.Role of aripiprazole in treatment-resistant schizophrenia.Emotion recognition in individuals at clinical high-risk for schizophrenia.Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.Polyunsaturated fatty acids in emerging psychosis.Polyunsaturated fatty acids in emerging psychosis: a safer alternative?Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.Predictors of longer-term outcome in the Vienna omega-3 high-risk study.Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls.Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians.Late-onset depression in elderly subjects from the Vienna Transdanube Aging (VITA) study.Are specific symptoms of depression predictive of Alzheimer's dementia?Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort.Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum.The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo.Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis.Duration of untreated psychosis in a high-income versus a low- and middle-income region.Psychotic-like experiences in esoterism: A twilight zone?Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values.Comprehension of metaphors in patients with schizophrenia-spectrum disorders.Does specific psychopathology predict development of psychosis in ultra high-risk (UHR) patients?The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders.In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.Facial and vocal affect perception in people at ultra-high risk of psychosis, first-episode schizophrenia and healthy controls.The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis.Affect recognition and functioning in putatively prodromal individuals.Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine.[Diagnosis of 22q11.2 deletion syndrome in the context of newly developed psychosis].NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical course.Case report: Intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapyFrüherkennung und Frühintervention der SchizophrenieBipolar disorder susceptibility region on chromosome 3q29 not confirmed in a case–control association study
P50
Q34180804-8B8CF23B-91B2-48CB-8776-9A115E9E883EQ34566534-260688C4-FFEE-4E34-8552-5D04812E54CDQ34665858-FA7072C7-F97C-4605-9D82-092DA7BA27F9Q36026776-9081DA42-14C6-422F-A31A-956BA6B47E8FQ36244988-B0A8A48C-4C2D-4387-A345-7B58CF54FB25Q37444594-125617F8-9B9F-4990-A512-3C7551924110Q37975279-243B2341-B8D0-4617-8E27-B394B35CBED8Q38214798-84CA8E5A-FDCA-4308-B26D-61B7E847002CQ38384201-FA441EC4-6D0B-4005-A1C4-FA96B61DD687Q38617091-8F7B80E2-1760-4F5B-BA53-530F19A14470Q40547436-C17F2D82-A66B-4200-A6C9-9467A2B2C3B2Q40934436-21A0AA22-FBCE-4718-83AB-E0A692714F51Q43135390-0EFF934E-9C85-4C68-8B37-1809CFA681C8Q43135395-09173F27-7CD1-452A-9010-D3407544BC69Q44165265-61BB30D0-78B6-42B5-BD26-159C6CEA8242Q44209895-BF57A3E4-598A-42C6-A7FE-7F750C76C1F4Q45897333-373AA3F4-ACD6-4404-9A39-EA8B77C45645Q46057214-8A4FF36E-4DE0-402B-8F81-8CE18C5D646BQ46113189-7A3B0E84-3845-4262-9A0F-8244F0AAD510Q46899585-8716BE54-6C2E-45AC-A47B-08CC78963D39Q47592454-1E7BDCD8-B38A-474F-9197-E70BB8E59DEBQ47622971-A844B0A2-DFA4-44EA-8A6D-45670F050055Q47716952-2BACB1C5-95E8-47D9-8621-8F3781EF1537Q47732326-B73211F4-70C5-4376-AE51-478C93EC1DC5Q47786934-71F7A5A8-76B8-44F0-881B-4DBB73639FAAQ48085282-1395D93B-0CC0-48D9-93DB-8B002E5DB832Q48554826-B184D91B-61E7-4377-AC50-E9B8A3809088Q49534918-37552659-DDAC-413A-A4CD-FDEDD6F72B6BQ50223962-A0006FFA-BE81-40A0-BE0B-CD01555B2489Q50573955-2FBDE9AD-3FC4-463A-B9CF-E5481084B386Q50577259-64508C82-1AF0-42CD-8653-51055BE9FF9EQ50743128-21B6FBD7-4203-4D8B-B842-03BF998DFAD4Q50744943-E2777C5A-C7C3-4D4D-AF88-00F0EE6CE129Q53503496-978A3CAB-7496-4BF7-B2D1-1A2822BB9413Q53522186-75D68C5C-90DA-418F-B449-38AA3C689635Q54380696-35BF37C9-840A-4A7D-B13D-65E0190191FDQ55330019-23C8FE9A-BA4E-4996-AC72-2E562DC030A6Q57738622-4DB99817-AF85-4573-A06E-DCD2B7EC9FFAQ57738646-7762B417-85D5-4095-8069-6313E8A2EEDCQ58806251-720F0D09-7134-4969-B0D5-C2B0B243890B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nilufar Mossaheb
@ast
Nilufar Mossaheb
@en
Nilufar Mossaheb
@es
Nilufar Mossaheb
@nl
Nilufar Mossaheb
@sl
type
label
Nilufar Mossaheb
@ast
Nilufar Mossaheb
@en
Nilufar Mossaheb
@es
Nilufar Mossaheb
@nl
Nilufar Mossaheb
@sl
prefLabel
Nilufar Mossaheb
@ast
Nilufar Mossaheb
@en
Nilufar Mossaheb
@es
Nilufar Mossaheb
@nl
Nilufar Mossaheb
@sl
P106
P21
P31
P496
0000-0002-7339-7219